Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Increase in unrecognized tax benefits that would impact effective tax rate

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept crl:IncreaseDecreaseInUnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's increase in unrecognized tax benefits that would impact effective tax rate.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's increase in unrecognized tax benefits that would impact effective tax rate?
Charles River Laboratories (CRL) reported increase in unrecognized tax benefits that would impact effective tax rate of $131.4M in Q1 2026.
How has Charles River Laboratories's increase in unrecognized tax benefits that would impact effective tax rate changed year-over-year?
Charles River Laboratories's increase in unrecognized tax benefits that would impact effective tax rate increased by 14500.0% year-over-year, from $900K to $131.4M.